This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n19http://linked.opendata.cz/resource/domain/vavai/projekt/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n5http://linked.opendata.cz/resource/domain/vavai/subjekt/
n4http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n6http://linked.opendata.cz/ontology/domain/vavai/riv/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023001%3A_____%2F12%3A00058445%21RIV13-MZ0-00023001/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023001%3A_____%2F12%3A00058445%21RIV13-MZ0-00023001
rdf:type
skos:Concept n4:Vysledek
rdfs:seeAlso
http://www.nel.edu/home.htm
dcterms:description
OBJECTIVES: A significant inter-individual variability in statin treatment efficacy is likely to have a strong genetic background. A candidate gene with the potential to influence statin treatment efficacy is SLCO1B1. This gene codes for the solute carrier organic anion transporter, which has been shown to regulate the hepatic uptake of statins and some other drugs. MATERIALS AND METHODS: The SLCO1B1 rs4149056 (T>C) polymorphism was successfully analysed in a group of 253 patients with dyslipidemia (treated with simvastin or atorvastatin, 10 or 20 mg per day) and 470 healthy normolipidemic controls. The polymorphism was analysed using nested PCR-RFLP. Lipid levels (total, LDL and HDL cholesterol; triglycerides) were analysed before and after 10-13 weeks of treatment. RESULTS: After treatment, as expected, there was a significant decrease both in the total cholesterol (7.60+-1.36 -> 5.37+-1.12 mmol/L, p<0.001) and LDL cholesterol (5.04+-1.34 -> 3.17+-0.99 mmol/L, p<0.001) levels. The distribution of the individual genotypes in the patients (TT=61.7%, CT=31.6%, CC=6.7%) was similar (p=0.35) to that of the normolipidemic controls (TT=64.4%, CT=31.3%, CC=4.3%). Homozygous CC males exhibited the lowest (delta -21.2+-7.2%) decrease of total cholesterol in contrast to the females, in whom the same genotype was associated with the highest (delta -33.5+-7.6 %) decrease (p=0.04 for gene-gender interaction). CONCLUSIONS: The results of our pilot study suggest possible gender-dependent effects of the rs4149056 variant within the SLCO1B1 gene on statin treatment efficacy. OBJECTIVES: A significant inter-individual variability in statin treatment efficacy is likely to have a strong genetic background. A candidate gene with the potential to influence statin treatment efficacy is SLCO1B1. This gene codes for the solute carrier organic anion transporter, which has been shown to regulate the hepatic uptake of statins and some other drugs. MATERIALS AND METHODS: The SLCO1B1 rs4149056 (T>C) polymorphism was successfully analysed in a group of 253 patients with dyslipidemia (treated with simvastin or atorvastatin, 10 or 20 mg per day) and 470 healthy normolipidemic controls. The polymorphism was analysed using nested PCR-RFLP. Lipid levels (total, LDL and HDL cholesterol; triglycerides) were analysed before and after 10-13 weeks of treatment. RESULTS: After treatment, as expected, there was a significant decrease both in the total cholesterol (7.60+-1.36 -> 5.37+-1.12 mmol/L, p<0.001) and LDL cholesterol (5.04+-1.34 -> 3.17+-0.99 mmol/L, p<0.001) levels. The distribution of the individual genotypes in the patients (TT=61.7%, CT=31.6%, CC=6.7%) was similar (p=0.35) to that of the normolipidemic controls (TT=64.4%, CT=31.3%, CC=4.3%). Homozygous CC males exhibited the lowest (delta -21.2+-7.2%) decrease of total cholesterol in contrast to the females, in whom the same genotype was associated with the highest (delta -33.5+-7.6 %) decrease (p=0.04 for gene-gender interaction). CONCLUSIONS: The results of our pilot study suggest possible gender-dependent effects of the rs4149056 variant within the SLCO1B1 gene on statin treatment efficacy.
dcterms:title
Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy
skos:prefLabel
Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy
skos:notation
RIV/00023001:_____/12:00058445!RIV13-MZ0-00023001
n4:predkladatel
n5:ico%3A00023001
n6:aktivita
n17:P
n6:aktivity
P(NT11307)
n6:cisloPeriodika
suppl. 2
n6:dodaniDat
n8:2013
n6:domaciTvurceVysledku
n9:6873472 n9:3241513 n9:4176456 n9:6513832
n6:druhVysledku
n16:J
n6:duvernostUdaju
n12:S
n6:entitaPredkladatele
n15:predkladatel
n6:idSjednocenehoVysledku
160115
n6:idVysledku
RIV/00023001:_____/12:00058445
n6:jazykVysledku
n18:eng
n6:klicovaSlova
polymorphism, SLCO1B1, statin, efficacy, gene-gender interaction
n6:klicoveSlovo
n7:polymorphism n7:efficacy n7:gene-gender%20interaction n7:SLCO1B1 n7:statin
n6:kodStatuVydavatele
SE - Švédské království
n6:kontrolniKodProRIV
[A4036D9E0DEF]
n6:nazevZdroje
Neuroendocrinology letters
n6:obor
n14:FA
n6:pocetDomacichTvurcuVysledku
4
n6:pocetTvurcuVysledku
6
n6:projekt
n19:NT11307
n6:rokUplatneniVysledku
n8:2012
n6:svazekPeriodika
33
n6:tvurceVysledku
Vrablík, M. Hubáček, Jaroslav Češka, R. Lánská, Věra Adámková, Věra Dlouhá, Dana
s:issn
0172-780X
s:numberOfPages
4